PAVmed Inc. (PAVM)
NASDAQ: PAVM · Real-Time Price · USD
0.7062
+0.0243 (3.56%)
At close: May 12, 2025, 4:00 PM
0.6613
-0.0449 (-6.36%)
After-hours: May 12, 2025, 6:15 PM EDT
PAVmed Revenue
In the year 2024, PAVmed had annual revenue of $3.00M with 22.15% growth. PAVmed had revenue of $10.00K in the quarter ending December 31, 2024, a decrease of -99.05%.
Revenue (ttm)
$3.00M
Revenue Growth
+22.15%
P/S Ratio
2.20
Revenue / Employee
$76,795
Employees
39
Market Cap
22.01M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PAVM News
- 11 days ago - PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025 - PRNewsWire
- 12 days ago - Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025 - PRNewsWire
- 18 days ago - NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD - PRNewsWire
- 4 weeks ago - Lucid Diagnostics Announces Closing of Public Offering of Common Stock - PRNewsWire
- 4 weeks ago - Lucid Diagnostics Announces Pricing of Public Offering of Common Stock - PRNewsWire
- 4 weeks ago - Lucid Diagnostics Announces Proposed Public Offering of Common Stock - PRNewsWire
- 5 weeks ago - Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - PRNewsWire
- 6 weeks ago - Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology - PRNewsWire